New Century Financial Group LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

New Century Financial Group LLC acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,125 shares of the specialty pharmaceutical company's stock, valued at approximately $388,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Fuller & Thaler Asset Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock valued at $115,681,000 after buying an additional 507,234 shares during the period. Darwin Global Management Ltd. purchased a new stake in Jazz Pharmaceuticals during the fourth quarter worth approximately $59,668,000. Dimensional Fund Advisors LP boosted its stake in Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after acquiring an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after acquiring an additional 315,608 shares during the last quarter. Finally, GMT Capital Corp raised its holdings in shares of Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock valued at $62,659,000 after buying an additional 296,800 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on JAZZ shares. Royal Bank of Canada decreased their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their target price for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Finally, Needham & Company LLC restated a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $184.00.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the transaction, the chief executive officer now owns 440,307 shares in the company, valued at approximately $54,487,991.25. The trade was a 0.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Seamus Mulligan purchased 100,000 shares of the business's stock in a transaction on Friday, May 9th. The stock was purchased at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the acquisition, the director now owns 100,000 shares in the company, valued at approximately $9,826,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 3,000 shares of company stock valued at $355,925 in the last three months. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Trading Down 1.6%

Shares of NASDAQ:JAZZ traded down $1.79 during midday trading on Friday, reaching $108.50. The company had a trading volume of 478,127 shares, compared to its average volume of 833,690. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The company has a fifty day simple moving average of $107.84 and a two-hundred day simple moving average of $120.56. The firm has a market cap of $6.69 billion, a price-to-earnings ratio of 15.28, a price-to-earnings-growth ratio of 1.04 and a beta of 0.33. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm's quarterly revenue was down .5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.68 earnings per share. Research analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.